Coccidiosis

BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (OTC PINK: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive efficacy results following its recent 42-day coccidiosis challenge study further demonstrating the effectiveness of its novel immune-modulating treatment for coccidiosis in broiler chickens. ZIVO’s product candidate for use in poultry feed is designed to boost immune response, allowing birds to effectively combat coccidiosis and reduce the negative effects of the disease without the use of antibiotics. With these and earlier test results, ZIVO will pursue a partnership with a global animal health company for commercializing its coccidiosis product. The study design was similar to that of a previously successful 28-day challenge study but was extended through 42 days to replicate real-world conditions of the broiler production industry. The results of the study in which the ZIVO treatment groups and a placebo control were blinded to the independent study contractor confirm previously reported positive effects of ZIVO’s non-antibiotic alternative for maintaining broiler health against coccidiosis. Notably, the study also showed that the performance of ZIVO’s product candidate was comparable to that of a market leading anticoccidial product. “We are delighted to report results that validate our prior 28-day study in broiler chickens, and we are particularly excited to report that our product performance compared favorably to a market leading product containing an antibiotic and an anti-coccidial chemical. The outcomes of our studies demonstrate that our coccidiosis treatment is efficacious in real-world conditions, yet without the undesirable characteristics associated with antibiotics and chemicals,” said John Payne, Chairman and Chief Executive Officer of ZIVO Bioscience. “Not only do our results show our candidate’s effectiveness in counteracting or eliminating adverse effects of coccidiosis on gastrointestinal health of broiler chickens, we are confident that similar results will be obtained in the commercial broiler production environment at cost parity with conventional antibiotic and antimicrobial interventions. As a result, our product exhibits promising potential to revolutionize poultry health management. Our next step is to use these results to engage a global animal health partner to complete licensing through the USDA and commercialize the product,” Mr. Payne added. About Coccidiosis Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billioni. Products for treating coccidiosis are mostly antibiotic- or ionophore-based, and no significant new commercial technology has been introduced in the past 60 years. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that industry and consumers alike wish to replace due to the risks of developing drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion. About ZIVO Bioscience ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit for more information. Forward Looking Statements Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected time frame for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future. i Blake, D.P., Knox, J., Dehaeck, B. et al. Re-calculating the cost of coccidiosis in chickens. Vet Res 51, 115 (2020).

A new study of 601 older adults found that those with higher serointensity -- or a higher concentration of antibiodies -- to the cat-borne parasite Toxoplasma gondii are more likely to show signs of frailty, including exhaustion, loss of muscle mass and other indications of declining health. T. Gondii has previously been associated with risk-taking behavior and mental illness. A common, cat-borne parasite already associated with risk-taking behavior and mental illness in humans may also contribute to exhaustion, loss of muscle mass, and other signs of "frailty" in older adults, suggests a study published Nov. 6 in the Journal of Gerontology: Medical Science. The research, by an international team of scientists including University of Colorado Boulder, University of Maryland School of Medicine and the University of A Coruña in Spain, is the latest to explore how the tiny, single-celled organism Toxoplasma gondii (T. gondii) could have big impacts on human health. "We often think of T. gondii infection as relatively asymptomatic, but this study highlights that for some people it may have significant health consequences later on," said co-author Christopher Lowry, a professor in the Department of Integrative Physiology at CU Boulder. Approximately 11% to 15% of people in the U.S. have been infected with T. gondii at some point and rates tend to be far higher in older individuals. In some countries, more than 65% have been infected. Once infected, people can unknowingly harbor the parasite for life. For the study, the team examined the blood of 601 Spanish and Portuguese adults over 65, along with measures of a common geriatric syndrome known as "frailty" -- which includes unintentional weight loss, tiredeness, loss of cognitive sharpness and other indications of declining health. A whopping 67% of study subjects were "seropositive" showing markers in their blood of a latent infection. The researchers did not, as they originally hypothesized, find an association between any infection to T. gondii and frailty. But they did find that, among those infected, those with higher "serointensity" or a higher concentration of antibodies to the parasite, were significantly more likely to be frail. Higher serointensity could reflect a more virulent or widespread infection, multiple infections or recent reactivation of a latent infection, the authors said. "This paper is important because it provides, for the first time, evidence of the existence of a link between frailty in older adults and intensity of the response to T. gondii infection," said co-author Blanca Laffon, a professor of psychobiology at the Interdisciplinary Centre of Chemistry and Biology at University of A Coruña. How cats spread T. gondii Wild and domestic felines are considered the definitive host of the parasite, while warm-blooded animals like birds and rodents serve as secondary hosts: When cats eat infected animals, T. gondii takes up residence and multiplies in their intestines, shedding eggs in their feces. People are typically infected via exposure to those eggs (via litter boxes, contaminated water or dirty vegetables) or by eating undercooked pork, lamb or other meat that's infested. Most people never know they've been infected, with only about 10% initially having brief flu-like symptoms. But T. gondii tends to linger dormant for decades, cloaked in cysts in muscle and brain tissue (specifically the emotion-processing region known as the amygdala) with some insidious impacts, mounting research suggests. In a creepy evolutionary trick seemingly designed to benefit the parasite's favorite host, rodents infected with T. gondii tend to lose their fear of felines, making it easier for cats to catch rats and mice. In the wild, infected chimpanzees have been shown to actually grow attracted to the smell of the urine of their feline predator, the leopard. People who have been infected also tend to engage in risky behavior, with research showing they tend to be more impulsive, more entrepreneurial and more likely to get in a car accident. They also have higher rates of schizophrenia, certain mood disorders, cognitive problems and are more likely to attempt suicide, according to research by Lowry and Dr. Teodor Postolache, a professor in the Department of Psychiatry at University of Maryland School of Medicine and senior author on the new study. A declining immune response? The authors caution that the new study does not prove that exposure to T. gondii causes frailty, but rather identifies a compelling association that warrants further study. They found that frail people with high T. gondii seropositivity also had higher levels of certain inflammatory markers, suggesting that infection with the parasite could exacerbate inflammation that already occurs with aging -- a.k.a. "inflammaging." Because latent T. gondii tends to hide out in muscle tissue, Postolache suspects it could also play a role in hastening sarcopenia, or age-related muscle wasting. Lowry's research centers around the impact microorganisms have on the immune system and, thus, mental health. He notes that many microbes that humans have evolved with impact health in a positive way -- a theory known as the Old Friends hypothesis. Even T. gondii may have health benefits we aren't yet aware of, he said. But in some cases, a switch flips, and friends become enemies. In the case of T. gondii, certain medications or immune compromising diseases like HIV or cancer can enable a latent infection to escape suppression and reactivate, with adverse effects. Even in people with healthy immune systems, Lowry notes, immune function can decline with age, potentially enabling dormant T. gondii to rear up. The researchers hope their study will inspire more research into the relationship between T. gondii and frailty, and ultimately lead to new ways of keeping the parasite from doing harm. For now, they encourage people -- especially pregnant and immune compromised people -- to take steps to avoid infection. Tips for preventing infection: Change litter box daily, and wash hands afterward. Avoid eating undercooked meat. Rinse fruits and vegetables. If pregnant or immunocompromised: Avoid changing the litter box if possible (T. gondii infection during pregnancy can cause serious problems to a developing fetus). Keep cats indoors. Avoid stray cats.

All test groups demonstrated statistically significant benefit in broiler health under simulated commercial conditions BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)-- Zivo Bioscience, Inc. (NASDAQ: ZIVO) (the “Company”), a biotech/agtech R&D company engaged in the development of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces positive results from a month-long coccidiosis trial in broiler chickens that was conducted by an independent veterinary research provider. The study evaluating the Company’s novel immune-modulating biologic for treating coccidiosis in broiler chickens examined multiple product lots as well as multiple product test concentrations and produced statistically significant positive outcomes in the treated groups. Coccidiosis is a protozoal disease that causes diarrhea, weight loss, decreased performance, and increased mortality in poultry. This disease represents a significant economic challenge for the global poultry industry, as indicated by a 2020 study that estimated annual costs ranging from $10 billion to $17 billion (Re-calculating the Cost of Coccidiosis in Chickens; Blake, D., Knox, J., et al.). Products for treating coccidiosis are mostly antibiotic or ionophore-based, and no commercially significant new technology has been introduced in the past 60 years. The disease challenge used in this trial closely replicated conditions often seen in commercial broiler production facilities experiencing a coccidiosis outbreak, including commercially relevant incidence and severity of intestinal lesions, mortality, and other disease related measures. Birds treated with ZIVO’s product candidate demonstrated statistically significant improvements across all measures of broiler health examined. Diseased chickens treated with elevated doses of ZIVO's product candidate exhibited reductions in disease-related effects to a level seen in healthy birds. “These results are very encouraging as they demonstrate our product’s potential to mitigate the effects of coccidiosis while acting through a highly desirable non-antibiotic mechanism of action. We now plan to launch the final phase of the product candidate’s validation, which involves a 42-day confirmatory study performed under broiler industry-relevant conditions such as those used in the present study. We expect to have results from this confirmatory study near the end of 2023,” said John Payne, CEO and Chairman of ZIVO Bioscience. The results of this recent study of multiple product batches, including product used in the inconclusive study earlier this year, align with those of over 20 prior successful trials that closely replicated disease levels observed in commercial production settings. Thus, validating that ZIVO’s product candidate maintains stability over an extended period, with no decrease in its effectiveness. As a result, ZIVO remains confident that its novel product candidate for broiler chickens presents a disruptive solution to coccidiosis, one of the most significant challenges facing the global poultry industry. "ZIVO’s biotech business is a significant driver of value creation, and we are prioritizing our coccidiosis candidate and working with the USDA’s Center for Veterinary Biologics on the regulatory path toward licensure of a product for the treatment and prevention of this disease. This strategy best optimizes value by achieving sustainable revenue in the shortest timeframe possible. In addition to the poultry market, our research suggests there are numerous additional health benefits and disease treatments to be derived from our proprietary algal culture for livestock, companion animals, and humans. We intend to pursue those additional opportunities, as well, should resources become available,” added Mr. Payne. About ZIVO Bioscience ZIVO Bioscience is a research and development company with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent pending inventions for applications in human and animal health. Please visit for more information. Forward Looking Statements Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including with respect to the Company’s product candidate’s potential to generate revenues and the expected time frame for results of future studies. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that we will be unable to increase production sufficient to meet our expected demand; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future. View source version on businesswire.com: Contacts ZIVO Bioscience Keith Marchiando, Chief Financial Officer (248) 452-9866 x130 kmarchiando@zivobioscience.com LHA Investor Relations Tirth T. Patel (212) 201-6614 tpatel@lhai.com Source: Zivo Bioscience, Inc. View this news release online at: